Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006460 | 0.86 | HSP90AA1 (0.45) | HSP90AB1HSP90AA1MEN1ALDH1A1GAA | |
| SCHEMBL5008459 | 0.80 | HSP90AA1 (0.50) | HSP90AB1HSP90AA1MEN1ALDH1A1GAA | |
| SCHEMBL5003247 | 0.78 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1 | |
| SCHEMBL4999314 | 0.78 | HSP90AA1 (0.46) | HSP90AB1HSP90AA1MEN1ALDH1A1GAA | |
| SCHEMBL5006529 | 0.78 | HSP90AB1 (0.43) | HSP90AB1HSP90AA1MEN1ALDH1A1GAA | |
| SCHEMBL5003564 | 0.75 | HSP90AA1 (0.40) | HSP90AB1HSP90AA1 | |
| SCHEMBL4999224 | 0.75 | HSP90AA1 (0.46) | HSP90AB1HSP90AA1MEN1ALDH1A1KMT2A | |
| SCHEMBL5002845 | 0.74 | HSP90AA1 (0.41) | HSP90AB1HSP90AA1 | |
| SCHEMBL4999336 | 0.74 | HSP90AA1 (0.40) | HSP90AB1HSP90AA1MEN1ALDH1A1GAA | |
| SCHEMBL5006570 | 0.72 | HSP90AA1 (0.51) | HSP90AB1HSP90AA1MEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116252-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116251-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116431-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116253-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-8399464-B2 | using a triazole compound; anticancer agent | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116252-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885MEN1 4815/4885 |
| US-20130116253-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885MEN1 4815/4885 |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885MEN1 4757/4885 |
| US-20130116251-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885MEN1 4815/4885 |
| US-20130116431-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885MEN1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.